400
UNIT 3 ■ Care of Patients With Psychiatric Disorders
Kranjac, D. (2016). Pharmacotherapy for smoking cessation in adults with neuropsychiatric illness. http://www.psychiatryadvisor.com /addiction/smoking-cessation-in-adults-with-neuropsychiatric -illness/article/518385 Lewis, S. F., Escalona, R., & Keith, S. J. (2017). The phenome nology of schizophrenia. In B. J. Sadock, V. A. Sadock, & P. Ruiz (Eds.), Comprehensive textbook of psychiatry (11th ed., pp. 1406–1425). Wolters Kluwer. Lysaker, P. H., Roe, D., & Buck, K. D. (2010). Recovery and well- ness amidst schizophrenia: Definitions, evidence, and the implications for clinical practice. Journal of the American Psychi- atric Nurses Association, 16 (1), 36–42. MacCabe, J. H., Wicks, S., Löfving, S., David, A. S., Berndtsson, Å., Gustafsson, J-E, Allebeck, P., & Dalman, C. (2013). Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: A Swedish longitudinal cohort study in males. JAMA Psychiatry 70 (3), 261–270. https://doi .org/10.1001/2013.jamapsychiatry.43 Matheson, S. L., Shepherd, A. M., & Carr, V. J. (2014). How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library. Psychological Med- icine—London, 44 (6), 3387–3405. https://doi.org/10.1017 /S0033291714000166 Mathews, M., Tesar, G. E., Fattal, O., & Muzina, D. J. (2013). Schizophrenia and acute psychosis. http://www.clevelandclinicmeded .com/medicalpubs/diseasemanagement/psychiatry-psychology /schizophrenia-acute-psychosis Miller, B. (2020). Schizophrenia: Clinical considerations in men versus women. Psychiatric Times. https://www.psychiatrictimes .com/view/schizophrenia-clinical-considerations-men -versus-women Miller, J. (2020). Schizophrenia: A broad Rx. Psychiatric Times. https:// www.psychiatrictimes.com/view/schizophrenia-a-broad-rx Mueser, K. T., Bond, G. R., & Drake, R. E. (2001). Communi- ty-based treatment of schizophrenia and other severe mental disorders: Treatment outcomes. Medscape General Medicine 3 (1) [formerly published in Medscape Psychiatry & Men- tal Health eJournal 6 (1), 2001]. http://www.medscape.com /viewarticle/430529 Nauert, R. (2015). Excess neurotransmitter in brain may trig- ger schizophrenia. Psych Central . http://psychcentral.com /news/2013/04/19/excess-neurotransmitter-in-brain-may -trigger-schizophrenia/53880.html Okazaki, S., Boku, S., Otsuka, I., Mouri, K., Aoyama, S., Shiroiwa, K., Sora, I., Fujita, A., Shirai, Y., Shirakawa, O., Kokai, M., & Hishimoto, A. (2016). The cell cycle-related genes as bio- markers for schizophrenia. Progress Neuropsychopharmacology and Biological Psychiatry, 70 (Suppl. 9), 85–91. https://doi.org /10.1016/j.pnpbp.2016.05.005 Os, J. V., & Reininghaus, U. (2017). The clinical epidemiology of schizophrenia. In B. J. Sadock, V. A. Sadock., & P. Ruiz (Eds.), Comprehensive textbook of psychiatry (10 ed., pp. 1445–1457). Wolters Kluwer. Radhakrishnan, R., Wilkinson, S. T., & D’Souza, D. C. (2014). Gone to pot—A review of the association between cannabis and psychosis. Frontiers in Psychiatry, 5 (54). https://doi.org /10.3389/fpsyt.2014.00054 Rezansoff, S., Moniruzzaman, A., Fazel, S., McCandless, L., Procyshyn, R., & Somers, J. M. (2016). Housing First improves adherence to antipsychotic medication among formerly homeless adults with schizophrenia: Results of a random- ized controlled trial. Schizophrenia Bulletin. https://doi.org /10.1093/schbul/sbw136 Roberts, L. W., Louie, A. K., Guerrero, A., Balon, R., Beresin, E. V., Brenner, A., & Coverdale, J. (2017). Premature mortality among people with mental illness: Advocacy in academic psy- chiatry. Academic Psychiatry, 41 , (4), 441–446. Savill, M., Banks, C., Khanom, H., & Priebe, S. (2015). Do negative symptoms of schizophrenia change overtime?
Chesney, E., Goodwin, G. M., & Fazel, S. (2014). Risks of all-cause and suicide mortality in mental disorders: A meta-review. World Psychiatry. https://doi.org/10.1002/wps.20128 Clark, S. R., Baune, B. T., Schubert, K. O., Lavoie, S., Smesny, S., Rice, S. M., & Amminger, G. P. (2016). Prediction of transi- tion from ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers. Translational Psychiatry, 6 (9), e897. https://doi.org/10.1038/tp.2016.170 Davis, J., Eyre, H., Jacka, F. N., Dodd, S., Dean, O., McEwen, S., Debnath, M., McGrath, J., Maes, M., Amminger, P., McGorry, P. D., Pantelis, C., & Berk, M. (2016). A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neuroscience and Biobehavioral Reviews, 65 , 185–194. https://doi.org/10.1016/j.neubiorev.2016.03.017 D’Souza, D. C., Singh, N., Elander, J., Carbuto, M., Pittman, B., Udo de Haes, J., Sjogren, M., Peeters, P., Ranganathan, M., & Schipper, J. (2012). Glycine transporter inhibitor attenu- ates the psychotomimetic effects of ketamine in healthy males: Preliminary evidence. Neuropsychopharmacology, 37 (4), 1036–1046. https://doi.org/10.1038/npp.2011.295 Druss, B. G., Zhao, L., Von Esenwein, S., Morrato, E. H., & Marcus, S. C. (2011). Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Medical Care, 49 (6), 599–604. Ernst, D. (2019). Novel treatment for schizophrenia gets FDA’s breakthrough therapy designation. https://www.psychiatryadvisor .com/home/topics/schizophrenia-and-psychoses/novel -treatment-for-schizophrenia-gets-fdas-breakthrough-therapy -designation/ Frankenburg, F. R. (2020). What factors affect the prognosis of schizophrenia? Medscape . https://www.medscape.com /answers/288259-13995/what-factors-affect-the-prognosis -of-schizophrenia Freudenreich, O. (2010). Differential diagnosis of psychotic symp- toms: Medical “mimics.” Psychiatric Times, 27 (12), 52–61. Harrisberger, F., Smieskova1, R., Vogler, C., Egli, T., Schmidt, A., Lenz, C., Simon, A. E., Riecher-Rössler, A., Papassotiropou- los, A., & Borgwardt, S. (2016). Impact of polygenic schizo- phrenia-related risk and hippocampal volumes on the onset of psychosis. Translational Psychiatry, 6 , e868. https://doi.org /10.1038/tp.2016.143 Hashimoto, K. (2006). Glycine transporter inhibitors as therapeu- tic agents for schizophrenia. Recent Patents on CNS Drug Discov- ery, 1 , 43–53. Herdman, T. H., Kamitsuru, S., & Lopes, C. T. (Eds.). (2021). NANDA International, Inc. nursing diagnoses: Definitions and clas- sification, 2021–2023 (12th ed.). Thieme. Howes, O., McCutcheon, R., & Stone, J. (2015). Glutamate and dopamine in schizophrenia: An update for the 21st century. Journal of Psychopharmacology (Oxford, England), 29 (2), 97–115. https://doi.org/10.1177/0269881114563634 Hu, W., MacDonald, M. L., Elswick, D. E., & Sweet, R. A. (2014). The glutamate hypothesis of schizophrenia: Evidence from human brain tissue studies [Abstract]. Annals of the New York Academy of Sciences, 1338 , 38–57. https://doi.org/10.1111 /nyas Institute of Medicine. (2003). Health professions education: A bridge to quality. Jablensky, A. (2017). Worldwide burden of schizophrenia. In B. J. Sadock, V. A. Sadock, & P. Ruiz (Eds.), Comprehensive textbook of psychiatry (11th ed., pp. 1425–1437). Wolters Kluwer. Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Addington, J., Estroff, S. E., Robinson, J., Penn, D. L., & Robinson, D. G. (2015). The RAISE early treatment program for first-episode psycho- sis: Background, rationale, and study design. The Journal of Clinical Psychiatry, 76 (3), 240–246. https://doi.org/10.4088 /JCP.14m09289
Powered by FlippingBook